Joshua D Lee
Joshua D. Lee, MD, MSc
NYU Langone Health - Professor, Department of Population Health, Division of General Medicine and Clinical Innovation
MD, University of Tennessee College of Medicine
MSc, Weill Cornell Graduate School of Medical Sciences
AB, Art and Archeology, Princeton University
Research Interests
Addiction pharmacotherapies, Primary care, Criminal justice
Joshua D. Lee is a Professor of Population Health and Medicine/General Internal Medicine and Clinical Innovation at NYU Langone Health. He is a clinician researcher focused on addiction pharmacotherapies, and is Director of the NYU ABAM Fellowship in Addiction Medicine. His research models the use of addiction pharmacotherapies in primary care and criminal justice populations. He has conducted multiple NIH and other clinical trials examining the use of extended-release naltrexone and buprenorphine opioid treatments in outpatient criminal justice involved-adults, in soon-to-be released jail inmates, and in community detox settings. Research on extended-release naltrexone for alcohol treatment has focused on primary care medical management. Dr. Lee graduated Princeton University (AB), the University of Tennessee School of Medicine (MD), and Weill Cornell Graduate School of Medical Sciences (MSc). He completed a residency and chief residency in Primary Care Internal Medicine at NYU/Bellevue Hospital Center and is certified in Addiction Medicine. He is currently an attending physician at Bellevue Hospital and in the New York City jails.
Principal Investigator, Impact of Jail-Based Methadone on Overdose, Recidivism, HIV and Health Outcomes, and Costs in New York City, 2011-2017. Active
Principal Investigator, Long-Acting Buprenorphine vs. Naltrexone Opioid Treatments in CJS-Involved Adults. Active
Principal Investigator, Extended-Release Naltrexone Opioid Treatment at Jail-to-Community Re-Entry. Completed
Principal Investigator, Extended-Release vs. Oral Naltrexone Alcohol Treatment in Primary Care. Completed


Vest N, Wenzel K, Choo TH, Pavlicova M, Rotrosen J, Nunes E, Lee JD, Fishman M (2023).
Trajectories of depression among patients in treatment for opioid use disorder: A growth mixture model secondary analysis of the XBOT trial
American Journal on Addictions, 32 (2), 291-300. doi: 10.1111/ajad.13371.

Tofighi B, Badiei B, Badolato R, Lewis CF, Nunes E, Thomas A, Lee JD (2023).
Integrating text messaging in a low threshold telebuprenorphine program for New York City residents with opioid use disorder during COVID-19: A pilot randomized controlled trial
Journal of Addiction Medicine [Epub 2023 Mar 31]. doi: 10.1097/ADM.0000000000001161.

Tofighi B, Marini C, Lee JD, Garland EL (2023).
Patient perceptions of integrating meditation-based interventions in office-based opioid treatment with buprenorphine: A mixed-methods survey
Journal of Addiction Medicine [Epub 2023 Mar 28]. doi: 10.1097/ADM.0000000000001160.

Lim S, Cherian T, Katyal M,, Goldfeld KS, McDonald R, Wiewel E, Khan M, Krawczyk N, Braunstein S, Murphy SM, Jalali A, Jeng PJ, MacDonald R, Lee JD (2023).
Association between jail-based methadone or buprenorphine treatment for opioid use disorder and overdose mortality after release from New York City jails 2011-2017
Addiction, 118 (3), 459-467. doi: 10.1111/add.16071. PMCID: PMC9898114.

Tofighi B, Lopez R, Araujo G, Lee JD, Samuels EA, Wightman RS, Butner J (2023).
Provider and administrator attitudes and experiences with implementing telebuprenorphine during the COVID-19 pandemic: A mixed-methods survey
Journal of Substance Use [Epub 2023 Jan 13]. doi: 10.1080/14659891.2023.2166609.


Lee JD, Friedmann PD, Kinlock TW, Nunes EV, Boney TY, Hoskinson RA, Wilson D, McDonald R, Rotrosen J, Gourevitch MN, Gordon M, Fishman M, Chen DT, Bonnie RJ, Cornish JW, Murphy SM, O'Brien CP (2016).
Extended-release naltrexone to prevent opioid relapse in criminal justice offenders
New England Journal of Medicine, 374 (13), 1232-1242. doi: 10.1056/NEJMoa1505409. PMCID: PMC5454800.

Lee JD, McDonald R, Grossman E, McNeely J, Laska E, Rotrosen J, Gourevitch MN (2015).
Opioid treatment at release from jail using extended-release naltrexone: A pilot proof-of-concept randomized effectiveness trial
Addiction, 110 (6), 1008-1014. doi: 10.1111/add.12894.

Lee JD, Grossman E, Truncali A, Rotrosen J, Rosenblum A, Magura S, Gourevitch M (2012).
Buprenorphine-naloxone maintenance following release from jail
Substance Abuse, 33 (1), 40-47. doi: 10.1080/08897077.2011.620475. PMCID: PMC3310898.

Dr. Lee's MyBibliography Profile
Selected Press